Ortiz-Cuaran: In france: NCT02511288 LIBIL - n=265, 767 smpls to-date. Using 36-gene Inivata InVisionFirst #AACR18
4:20pm April 15th 2018 via Hootsuite
Ortiz-Cuaran: Clinical utility in observation - mech of resist, ctDNA dynamics under trtmt, determinant of ctDNA detection #AACR18
4:19pm April 15th 2018 via Hootsuite
Ortiz-Cuaran: Showing with 1st-line, 1st gen TKI's Erlotinib and Osimertinib. Sometimes transition to SCLC. T790M ~70-80%, others #AACR18
4:18pm April 15th 2018 via Hootsuite
Sandra Ortiz-Cuaran (Leon Berard, Lyon FR): Longitudinal ctDNA profiling of EGFR-mutated NSCLC patients treated with EGFR-TKI's #AACR18
4:16pm April 15th 2018 via Hootsuite
Coukos: End with a plea for Systems Immunology, need to rethink interlocking lab and informatics domains. Integrated analyses #AACR18
12:52pm April 15th 2018 via Hootsuite
Coukos: ID'd neo-epitope speci T-cells in ovarian tumors '18 ref https://t.co/IJaIvQ453S #AACR18
12:49pm April 15th 2018 via Hootsuite
Coukos: Doing TCR sequencing: ovariant tumor-spec TILs in islets, absent from stroma #AACR18
12:43pm April 15th 2018 via Hootsuite
Coukos: Are OvCa TILs tumor-spec? Dives into showing they are, and which Ags they are specific for #AACR18
12:41pm April 15th 2018 via Hootsuite
Coukos: '03 NEJM https://t.co/jruDIpVK09 OS much better w/intra-tumoral T-cells. Meta analysis n=1782. #AACR18
12:38pm April 15th 2018 via Hootsuite
George Coukos (Univ Lausanne CH) Mobilizing immunity against ovarian cancer #AACR18
12:36pm April 15th 2018 via Hootsuite
Rivas: Three pending adjuvant StgII clin trials: ECOG1609, SWOG1404, and CheckMate 915 #AACR18
12:34pm April 15th 2018 via Hootsuite
Eggermont: NEJM article with all these results now online. https://t.co/YW4pf8AL98 #AACR18
12:21pm April 15th 2018 via Hootsuite
Eggermont: ITT overall popln, HR 0.57, 18 mos RFS 18.2% diff; PD-L1+ HR 0.54, 18 mos RFS 19.7% diff #AACR18
12:18pm April 15th 2018 via Hootsuite
Eggermont: Relapse rate - almost double w/placebo. AE rate was 14% w/Pembro. Shows examples of immune-related AEs #AACR18
12:15pm April 15th 2018 via Hootsuite
Eggermont: 43% reduction in relapse - curves are divergent, similar results for PD-L1+ and PD-L1-. #AACR18
12:13pm April 15th 2018 via Hootsuite
Eggermont: Will they do as well as those w/Pembro right after surgery? 2.5y - answer to this crucial Q, adjuvant Rx for all #AACR18
12:04pm April 15th 2018 via Hootsuite
Eggermont: KEYNOTE-54: StgIII cutaneous melanoma n=1019 #AACR18 Adjuvant Rx, relapse unblinded, placebo gp cross-over to Pembro Rx
Eggermont: Reviews Old era (IFN '96-09) StgIII melanoma: 'the whole scene has changed' w/Ipi, Nivo, Pembro, Dabrafenib+Trametinib #AACR18
12:01pm April 15th 2018 via Hootsuite
Eggermont: BRAF + MEK inh for adv melnoma cp to PD-1inh: the curve flattens at 12 mo 60% durable 3y response #AACR18
12:00pm April 15th 2018 via Hootsuite
Eggermont: Prembro (anti-PD-1) avoids PD1-PDL1/2 bidning (that suppresses CTL activity) OS curve from '17 https://t.co/tmzgPhHgxw #AACR18
11:59am April 15th 2018 via Hootsuite
Alex Eggermont (Gustave Roussy FR) Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma KEYNOTE-054 #AACR18
11:56am April 15th 2018 via Hootsuite
Sharma: Concl: multiple checkpoints exist, and are dynamic in expression. Shd be evaluated both pre- and on-treatment #AACR18
11:54am April 15th 2018 via Hootsuite
Sharma: #AACR18 Localized oncolytic virotherapy paper: STM '14 https://t.co/q3jVWSzkdk
11:51am April 15th 2018 via Hootsuite
Sharma: Engage innate immune resp w/oncolytic viruses (toll-like receptor). Newcastle disease virus Rx leads to T-cell infiltration #AACR18
11:50am April 15th 2018 via Hootsuite
Sharma: Shows data fropm VISTA clin trial to turn 'hot' to 'cold' in PrCa. '17 ref https://t.co/xlqHLlDygi #AACR18
11:46am April 15th 2018 via Hootsuite
Sharma: Onto ICOS - belongs to CD28/CTLA-4 family. Clinical trials ongoing. Agonsitic anti-CD40 improves anti-tumor responses #AACR18
11:43am April 15th 2018 via Hootsuite
Sharma: Can you do 'reverse translation'? MDA setup Cancer ImmunoRx clin trials (113 across 18 depts) 3200 enrolled interacts w/lab #AACR18
11:38am April 15th 2018 via Hootsuite
Sharma: Can you enable pt selection for mono vs combo Rx? >1000 clinical trials - the clin studies outstrip basic science. #AACR18
11:36am April 15th 2018 via Hootsuite
Sharma: CTLA-4 blockage - now PD1, PD-L1. Known that combinations are more effective, but still key quesitons remain #AACR18
11:35am April 15th 2018 via Hootsuite
Sharma: +/- signals regulate Tcell responses. Two signals are req'd: CD28, and MHC, CD28+B7, also CTLA-4 outcompetes CD28 #AACR18
11:33am April 15th 2018 via Hootsuite
Padmanee Sharma (MD Anderson TX) Immune checkpoint therapy: From CTLA-4 to PD-1/PD-L1 and beyond #AACR18
11:31am April 15th 2018 via Hootsuite
Pantel: Reviews new efforts - EU Marie Curie Network for lung, LIPSY for prostate. #AACR18
11:29am April 15th 2018 via Hootsuite
Pantel: Points out involvement with CANCER-ID, an EU effort for standardization. Emph checkpt inh Rx, immune markers, mut loads #AACR18
11:28am April 15th 2018 via Hootsuite
Pantel: miRNAs also impt. Real-time monitoring to Rx applicable. Indep validation needed '18 Nature Biotech https://t.co/3yE7gwOa59 #AACR18
11:27am April 15th 2018 via Hootsuite
Pantel: Using MassArray of ctDNA in NSCLC in pts with brain mets, monitoring tumor evolution (poster here) #AACR18
11:25am April 15th 2018 via Hootsuite
Pantel: #AACR18 Landmark '14 paper EGFR in plasma cp to tumor in NSCLC https://t.co/xksZpUsqQX
11:23am April 15th 2018 via Hootsuite
Pantel: Hamburg City Health study started '15, 45K individuals (ongoing) #AACR18
11:22am April 15th 2018 via Hootsuite
Pantel: Lo's NEJM '17 of 20K nasopharengeal samples. And Papadopoulos Science '18 ctDNA 16 genes and protein markers combo #AACR18
11:21am April 15th 2018 via Hootsuite
Pantel: Points out ctDNA challenge due to dilution into bloodstream. Older people will have mutations in blood. #AACR18
Pantel: sc CNVs - gains and losses in brain metastatis (unpubl) interesting implications #AACR18
11:20am April 15th 2018 via Hootsuite
Pantel: #AACR18 mPC after first and second line Rx: AR-V7 expression from '17 ref https://t.co/LWOaLDPW0a
11:19am April 15th 2018 via Hootsuite
Pantel: #AACR18 Shows figure from this paper https://t.co/XghReREQNo In advanced pts: look at Rx targets, resistance mechanisms
11:17am April 15th 2018 via Hootsuite
Pantel: One technique of theirs is nanodots. CTC xenografts, and cell lines. CTC counts assoc'd with poor prognosis #AACR18
11:16am April 15th 2018 via Hootsuite
Pantel: #AACR18 Can use labels Abs or negative-selection. Or physical char's - size, deformity, electric charge https://t.co/TBU4Ac7dgx
11:15am April 15th 2018 via Hootsuite
Pantel: Loss of impt tumor clones b/c heterogeneity; sequential biopsies of tissue not feasible. Shows growth in PubMed CTC > ctDNA #AACR
11:13am April 15th 2018 via Hootsuite
Pantel: Def'n: analysis of CTCs or CTC products - DNA, miRNA, EVs in blood or other bodily fluids. Tissue biopsy still the std #AACR18
11:12am April 15th 2018 via Hootsuite
Klaus Pantel (UMC Hamburg DE) Liquid biopsy: Novel technologies and clinical applications #AACR18
11:11am April 15th 2018 via Hootsuite
The final #AACR18 award for extraordinary scientific innovation to Phil Sharp: '93 Nobelist for RNA splicing.
10:58am April 15th 2018 via Hootsuite
Foti: AstraZeneca/MedImmune funding $2M+ for creative approach for training/mentoring, clinical fellowships, Susan Galbraith AZ UK #AACR18
10:37am April 15th 2018 via Hootsuite
#AACR18 J&J funded the largest grant to AACR ever - $4.9M - applied to three grants on lung ca.
10:34am April 15th 2018 via Hootsuite
